Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development

被引:32
作者
Andreas, C. J. [1 ]
Rosenberger, J. [1 ]
Butler, J. [2 ]
Augustijns, P. [3 ]
McAllister, M. [4 ]
Abrahamsson, B. [5 ]
Dressman, J. [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Technol, Frankfurt, Germany
[2] GlaxoSmithKline R&D, Prod Dev & Supply, Ware, Herts, England
[3] Katholieke Univ Leuven, Drug Delivery & Disposit, Leuven, Belgium
[4] Pfizer PGRD, Drug Prod Design, Sandwich, Kent, England
[5] AstraZeneca R&D, Dept Global Med Dev, Molndal, Sweden
关键词
Dissolution; Decision tree; Formulation; Oral absorption; PBPK; Biopharmaceutics classification system (BCS); TRANSFER BIOGIT SYSTEM; SOLUBLE WEAK BASE; GASTROINTESTINAL TRANSFER; VIVO PERFORMANCE; SMALL-INTESTINE; DISSOLUTION MEDIA; DRUG ABSORPTION; TEST APPARATUS; TEST DEVICE; MODELS;
D O I
10.1016/j.ejpb.2018.07.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The EU research initiative OrBiTo (oral biopharmaceutics tools) involving partners from academia, pharmaceutical industry, small medium enterprises and a regulatory agency was launched with the goal of improving tools to predict the absorption of drugs in humans and thereby accelerating the formulation development process. The OrBiTo project was divided into four work packages (WP), with WP2 focusing on characterization of drug formulations. The present work introduces the OrBiTo WP2 Decision Tree, which is designed to assist the investigator in choosing the most appropriate in vitro methods for optimizing the oral formulation design and development process. The WP2 Decision Tree consists of four stages to guide the investigator. At the first stage, the investigator is asked to choose the formulation type of interest. At the second stage, the investigator is asked to identify which type of equipment (compendial/modified/noncompendial) is preferred/available. At the third stage, characteristics of the active pharmaceutical ingredient (API) are evaluated and in the fourth stage of the decision tree, suitable experimental protocols are recommended. A link to the living Decision Tree document is provided, and we now invite the pharmaceutical sciences community to apply it to current research and development projects and offer suggestions for improvement and expansion.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 39 条
[1]   Mechanistic investigation of the negative food effect of modified release zolpidem [J].
Andreas, Cord J. ;
Pepin, Xavier ;
Markopoulos, Constantinos ;
Vertzoni, Maria ;
Reppas, Christos ;
Dressman, Jennifer B. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 102 :284-298
[2]   Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine [J].
Andreas, Cord J. ;
Tomaszewska, Irena ;
Muenster, Uwe ;
van der Mey, Dorina ;
Mueck, Wolfgang ;
Dressman, Jennifer B. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 105 :193-202
[3]   In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release [J].
Andreas, Cord J. ;
Chen, Ying-Chen ;
Markopoulos, Constantinos ;
Reppas, Christos ;
Dressman, Jennifer .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 97 :39-50
[4]   Application and Validation of an Advanced Gastrointestinal In Vitro Model for the Evaluation of Drug Product Performance in Pharmaceutical Development [J].
Barker, Richard ;
Abrahamsson, Bertil ;
Kruusmagi, Martin .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (11) :3704-3712
[5]   Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System [J].
Berben, Philippe ;
Brouwers, Joachim ;
Augustijns, Patrick .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (01) :250-256
[6]   Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs [J].
Bergstrom, Christel A. S. ;
Holm, Rene ;
Jorgensen, Soren Astrup ;
Andersson, Sara B. E. ;
Artursson, Per ;
Beato, Stefania ;
Borde, Anders ;
Box, Karl ;
Brewster, Marcus ;
Dressman, Jennifer ;
Feng, Kung-I. ;
Halbert, Gavin ;
Kostewicz, Edmund ;
McAllister, Mark ;
Muenster, Uwe ;
Thinnes, Julian ;
Taylor, Robert ;
Mullertz, Anette .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 57 :173-199
[7]   Advances and challenges in PBPK modeling - Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base [J].
Berlin, Mark ;
Ruff, Aaron ;
Kesisoglou, Filippos ;
Xu, Wei ;
Wang, Michael Hong ;
Dressman, Jennifer B. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 93 :267-280
[8]   Prediction of oral absorption of cinnarizine - A highly supersaturating poorly soluble weak base with borderline permeability [J].
Berlin, Mark ;
Przyklenk, Karl-Heinz ;
Richtberg, Annette ;
Baumann, Wolfgang ;
Dressman, Jennifer B. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (03) :795-806
[9]   IVIVC in Oral Absorption for Fenofibrate Immediate Release Tablets Using a Dissolution/Permeation System [J].
Buch, Philipp ;
Languth, Peter ;
Kataoka, Makoto ;
Yamashita, Shinji .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (06) :2001-2009
[10]   Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model [J].
Carino, SR ;
Sperry, DC ;
Hawley, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) :116-125